| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 859 | 2015 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 531 | 2021 |
| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 456 | 2020 |
| Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells AK Pathak, M Bhutani, AS Nair, KS Ahn, A Chakraborty, H Kadara, ... Molecular cancer research 5 (9), 943-955, 2007 | 309 | 2007 |
| IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras–mutant lung cancer MS Caetano, H Zhang, AM Cumpian, L Gong, N Unver, EJ Ostrin, S Daliri, ... Cancer research 76 (11), 3189-3199, 2016 | 218 | 2016 |
| Circulating tumor cell detection technologies and clinical utility: Challenges and opportunities Z Habli, W AlChamaa, R Saab, H Kadara, ML Khraiche Cancers 12 (7), 1930, 2020 | 210 | 2020 |
| Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up H Kadara, M Choi, J Zhang, ER Parra, J Rodriguez-Canales, SG Gaffney, ... Annals of Oncology 28 (1), 75-82, 2017 | 203 | 2017 |
| Comprehensive T cell repertoire characterization of non-small cell lung cancer A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ... Nature communications 11 (1), 603, 2020 | 201 | 2020 |
| Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma T Cascone, MH Herynk, L Xu, Z Du, H Kadara, MB Nilsson, CJ Oborn, ... The Journal of clinical investigation 121 (4), 1313-1328, 2011 | 186 | 2011 |
| Ets2 mediated tumor suppressive function and met oncogene inhibition in human non–small cell lung cancer M Kabbout, MM Garcia, J Fujimoto, DD Liu, D Woods, CW Chow, ... Clinical cancer research 19 (13), 3383-3395, 2013 | 170 | 2013 |
| High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and mutation MI Nunez, C Behrens, DM Woods, H Lin, M Suraokar, H Kadara, ... Journal of thoracic oncology 7 (5), 833-840, 2012 | 161 | 2012 |
| EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non–small cell lung carcinoma C Behrens, LM Solis, H Lin, P Yuan, X Tang, H Kadara, E Riquelme, ... Clinical cancer research 19 (23), 6556-6565, 2013 | 160 | 2013 |
| Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... DOI: https://doi. org/10.1158/2159-8290. CD-14-1236, 860-877, 2012 | 159 | 2012 |
| Image analysis–based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non–small cell lung carcinoma patients ER Parra, C Behrens, J Rodriguez-Canales, H Lin, B Mino, J Blando, ... Clinical Cancer Research 22 (24), 6278-6289, 2016 | 155 | 2016 |
| Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance Y Chu, E Dai, Y Li, G Han, G Pei, DR Ingram, K Thakkar, JJ Qin, M Dang, ... Nature medicine 29 (6), 1550-1562, 2023 | 151 | 2023 |
| Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung P Yuan, H Kadara, C Behrens, X Tang, D Woods, LM Solis, J Huang, ... PloS one 5 (2), e9112, 2010 | 146 | 2010 |
| 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy G Han, G Yang, D Hao, Y Lu, K Thein, BS Simpson, J Chen, R Sun, ... Nature communications 12 (1), 5606, 2021 | 144 | 2021 |
| Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome LM Solis, C Behrens, MG Raso, HY Lin, H Kadara, P Yuan, H Galindo, ... Cancer 118 (11), 2889-2899, 2012 | 136 | 2012 |
| Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial T Cascone, CH Leung, A Weissferdt, A Pataer, BW Carter, MCB Godoy, ... Nature medicine 29 (3), 593-604, 2023 | 131 | 2023 |
| Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer Y Kudo, C Haymaker, J Zhang, A Reuben, DY Duose, J Fujimoto, ... Annals of Oncology 30 (9), 1521-1530, 2019 | 130 | 2019 |
